| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||
| Acetyl-L-carnitine (ALC, ALCAR) — an endogenous acetylated derivative of L-carnitine that participates in the carnitine/acylcarnitine system for shuttling acyl groups between cellular compartments and buffering mitochondrial acetyl-CoA/CoA balance. A naturally occurring molecule involved in mitochondrial energy metabolism. It is a small-molecule nutrient/“mitochondrial co-factor” used clinically or as a supplement in various jurisdictions, with mechanistic relevance to fatty-acid oxidation flux control and (context-dependent) support of cytosolic acetyl-CoA pools that feed lipid synthesis and protein acetylation. In oncology contexts, its relevance is primarily metabolic (substrate handling and acetyl unit trafficking) plus supportive-care use cases rather than a validated anticancer drug modality. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral dosing produces measurable systemic exposure with reported Tmax on the order of hours and plasma half-life on the order of hours in small human PK studies; tissue distribution depends on carnitine transporters (e.g., OCTN2) including across the blood–brain barrier. Systemic levels achievable with typical supplementation are generally far below the high millimolar exposures sometimes used in in-vitro cancer studies, so concentration-driven cytotoxic claims often have limited translational relevance unless a mechanism is triggered at low exposure or via compartmental flux effects. In-vitro vs systemic exposure relevance: Many reported “direct anticancer” effects occur at supraphysiologic concentrations and may not map to achievable plasma/tissue levels; flux-level effects on acetyl-group trafficking and FAO may be more relevant at physiologic ranges but are strongly context-dependent (tumor type, ACLY/ACSS2 status, nutrient environment). Clinical evidence status: Supportive-care evidence is mixed and indication-specific; a large randomized trial found no benefit for taxane-related chemotherapy-induced peripheral neuropathy at 12 weeks and worsening at longer follow-up, arguing against routine use for CIPN prevention. Evidence for cancer-related fatigue/cachexia has been explored (often as L-carnitine class rather than ALCAR specifically) with meta-analytic conclusions generally not supporting efficacy in lower-bias trials. -ALC supports mitochondrial energy metabolism by transporting fatty acids into mitochondria.-Antioxidant effects: Reduces oxidative stress and lipid peroxidation. -In cancer patients with fatigue or cachexia (wasting), ALC can improve energy metabolism and physical function. -Acetyl-L-carnitine (ALC or ALCAR) levels are often reduced in Alzheimer's disease (AD) — especially in the brain and cerebrospinal fluid (CSF). -ALC is present at high concentrations in the brain -Carnitine is important in the β-oxidation of fatty acids and the acetyl portion can be used to maintain acetyl-CoA levels -ALC is active in cholinergic neurons, where it is involved in the production of acetylcholine -ALC significantly reduces Aβ-induced cytotoxicity, protein oxidation and lipid peroxidation in a concentration-dependent manner. -ALC can cause an increase in the level of ADAM10 Acetyl-L-carnitine: mechanistic pathway ranking in cancer contexts
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped. -Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation. -HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer. -HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells. -HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis. -HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type. -While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes. -HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases. -HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells. |
| 5326- | ALC, | L-Carnitine Is an Endogenous HDAC Inhibitor Selectively Inhibiting Cancer Cell Growth In Vivo and In Vitro |
| - | vitro+vivo, | Liver, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:350 Target#:140 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid